IBRX Stock Poised for Breakout Quarter: Anktiva Launches Phase 2 Long COVID Trial Amid European Expansion Plans
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 30 2026
0mins
Should l Buy IBRX?
Source: stocktwits
Phase 2 Long COVID Study Launch: The company has initiated a Phase 2 study to assess the effectiveness of Anktiva in improving recovery from long COVID by restoring immune cells, with plans to enroll about 20 participants and complete the study by October.
Expansion Beyond Cancer: Anktiva's platform has expanded its applications beyond cancer treatments to include severe pneumonia, sepsis, and acute respiratory distress syndrome, indicating a broader potential for immune activation therapies.
Stock Performance and Market Sentiment: Shares of ImmunityBio (IBRX) have surged over 270% this year, significantly outperforming the S&P Biotech ETF, reflecting positive market sentiment and renewed interest in the company's therapies.
Regulatory Progress and Future Plans: The therapy has been added to approved drug lists for bladder cancer and is being positioned as a recommended option for patients who do not respond to standard therapies, with ongoing efforts to expand its use in various diseases.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy IBRX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on IBRX
Wall Street analysts forecast IBRX stock price to fall
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 7.600
Low
5.00
Averages
7.33
High
9.00
Current: 7.600
Low
5.00
Averages
7.33
High
9.00
About IBRX
Immunitybio, Inc. is a vertically integrated, clinical-stage biotechnology company developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Using its applied science and platforms to treat cancers, including the development of potential cancer vaccines, as well as developing immunotherapies and cell therapies to reduce or eliminate the need for standard high-dose chemotherapy. Its platforms and their associated product candidates are designed to attack cancer and infectious pathogens by activating both the innate immune system, including NK cells, dendritic cells, and macrophages, as well as the adaptive immune system comprising B and T cells, in an orchestrated manner. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins, vaccine vectors, and cell therapies. Its biologic commercial product candidate, Anktiva, is an IL-15 superagonist antibody-cytokine fusion protein.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
ImmunityBio Faces Class Action Lawsuit Over Misleading Claims
- Class Action Initiated: Robbins LLP reminds shareholders of a class action filed on behalf of investors who purchased ImmunityBio, Inc. (NASDAQ:IBRX) securities between January 19, 2026, and March 25, 2026, highlighting concerns over potential misleading actions by the company.
- FDA Warning Letter Exposed: During the class period, CEO Soon-Shiong was accused of overstating the capabilities of the lead product ANKTIVA, particularly after a March 24, 2026, FDA warning letter indicated that promotional communications could mislead investors by claiming ANKTIVA could cure all cancers.
- Significant Stock Drop: Following the FDA warning letter, ImmunityBio's stock fell by 21% on March 24, 2026, losing $1.98 per share and closing at $7.42, reflecting market concerns about the company's future prospects.
- Shareholder Action Guidance: Shareholders can submit applications by May 26, 2026, to serve as lead plaintiffs in the class action, representing other shareholders and emphasizing the importance of corporate governance and executive accountability.
See More
ImmunityBio Faces Federal Securities Class Action
- Lawsuit Deadline: Investors in ImmunityBio must apply to be lead plaintiffs in the federal securities class action by May 26, 2026, as late applications will not be considered by the court, which could significantly impact the company's litigation strategy and future legal standing.
- False Advertising Allegations: The lawsuit alleges that Executive Chairman Patrick Soon-Shiong materially overstated the capabilities of Anktivas, an FDA-approved IL-15 receptor agonist, in public statements, potentially misleading investors about the company's prospects and affecting their investment decisions.
- FDA Warning Letter: On March 24, 2026, the FDA issued a warning letter to ImmunityBio, stating that its TV ad and podcast were deemed “false or misleading,” which could damage the company's reputation and impact its market performance moving forward.
- Stock Price Plunge: Following the FDA's warning, ImmunityBio's stock price fell from $9.40 per share on March 23, 2026, to $7.41, a decline of 21.2%, reflecting a significant loss of market confidence in the company's future, which may hinder its financing and operational capabilities.
See More
Securities Fraud Class Action Filed Against ImmunityBio, Inc.
- Lawsuit Background: Kessler Topaz Meltzer & Check, LLP has filed a securities fraud class action against ImmunityBio, Inc. (NASDAQ:IBRX) on behalf of investors who purchased shares between January 19, 2026, and March 24, 2026, highlighting serious concerns regarding the company's financial transparency.
- False Statement Allegations: The lawsuit alleges that ImmunityBio made materially false and misleading statements during this period, particularly regarding the capabilities of its cancer vaccine Anktiva, which misled investors about the company's prospects and could negatively impact its stock price and market trust.
- FDA Warning Impact: On March 24, 2026, the FDA issued a warning letter to ImmunityBio, citing inaccurate claims made by executives about Anktiva on a podcast, resulting in a 21.12% drop in stock price, raising investor concerns about corporate governance and compliance.
- Investor Action Recommendations: Investors are encouraged to apply for lead plaintiff status by May 26, 2026, to represent all affected investors, indicating a focus on the company's future legal and financial responsibilities.
See More
ImmunityBio Faces Securities Class Action Lawsuit
- Lawsuit Background: ImmunityBio faces a securities class action lawsuit following misleading efficacy claims made by its Chief Scientific Officer regarding its lead biologic product Anktiva, resulting in a stock price drop of over 21% on March 24, 2026, erasing nearly $2 billion in market capitalization.
- FDA Warning Letter: The FDA issued a warning letter to ImmunityBio, stating that its promotional materials, including a podcast and TV ad, contained false or misleading information, particularly regarding claims that Anktiva could cure all cancers, lacking sufficient clinical data to support such assertions.
- Investor Rights: National shareholder rights firm Hagens Berman is investigating whether ImmunityBio violated federal securities laws, urging investors who suffered significant losses to submit claims and encouraging witnesses to provide information to assist in the investigation.
- Market Reaction: The stock price decline following the FDA warning and subsequent lawsuit reflects market concerns about ImmunityBio's future prospects, potentially impacting its ability to raise funds and maintain investor confidence.
See More
ImmunityBio Class Action Reminder for Investors
- FDA Warning Letter: On March 24, 2026, the FDA issued a warning to ImmunityBio, stating that Executive Chairman Patrick Soon-Shiong made false claims on a podcast regarding the company's lead biologic product, Anktiva, asserting it could 'cure and prevent all cancer,' exposing the company to legal risks.
- Stock Price Plunge: Following the FDA warning, ImmunityBio's stock price fell by $1.98, or 21.12%, closing at $7.42 per share, which directly impacted investors' asset values and resulted in significant losses.
- Class Action Context: The class action lawsuit alleges that the company made materially false and misleading statements during the class period, failing to disclose the true capabilities of Anktiva, which may mislead investors about the company's prospects and affect future investment decisions.
- Investor Action Notice: Investors are reminded to file their lead plaintiff motions by May 26, 2026, to seek compensation for their investment losses, highlighting the importance of timely action in the legal process.
See More
ImmunityBio Faces Securities Class Action Lawsuit
- Lawsuit Timeline: Investors must file Lead Plaintiff applications by May 26, 2026, to participate in the securities class action against ImmunityBio, covering stock transactions from January 19 to March 24, 2026, highlighting investor concerns over potential losses.
- FDA Warning Impact: Following a March 13, 2026, warning letter from the FDA indicating misleading advertising for Anktiva, ImmunityBio's stock price plummeted by 21% or $1.98 per share on March 24, 2026, demonstrating the direct impact of regulatory risks on the company's valuation.
- Legal Accountability: The lawsuit alleges that ImmunityBio and its executives failed to disclose material information during the class period, violating federal securities laws, indicating significant deficiencies in the company's transparency that could lead to severe legal repercussions.
- Investor Rights Protection: Kahn Swick & Foti law firm urges affected investors to contact their managing partner to understand their legal rights, emphasizing the importance of seeking compensation in securities fraud cases, reflecting a commitment to protecting investor interests.
See More
ImmunityBio Faces Class Action Lawsuit Over Misleading Claims
- Class Action Initiated: Robbins LLP reminds shareholders of a class action filed on behalf of investors who purchased ImmunityBio, Inc. (NASDAQ:IBRX) securities between January 19, 2026, and March 25, 2026, highlighting concerns over potential misleading actions by the company.
- FDA Warning Letter Exposed: During the class period, CEO Soon-Shiong was accused of overstating the capabilities of the lead product ANKTIVA, particularly after a March 24, 2026, FDA warning letter indicated that promotional communications could mislead investors by claiming ANKTIVA could cure all cancers.
- Significant Stock Drop: Following the FDA warning letter, ImmunityBio's stock fell by 21% on March 24, 2026, losing $1.98 per share and closing at $7.42, reflecting market concerns about the company's future prospects.
- Shareholder Action Guidance: Shareholders can submit applications by May 26, 2026, to serve as lead plaintiffs in the class action, representing other shareholders and emphasizing the importance of corporate governance and executive accountability.
See More
ImmunityBio Faces Federal Securities Class Action
- Lawsuit Deadline: Investors in ImmunityBio must apply to be lead plaintiffs in the federal securities class action by May 26, 2026, as late applications will not be considered by the court, which could significantly impact the company's litigation strategy and future legal standing.
- False Advertising Allegations: The lawsuit alleges that Executive Chairman Patrick Soon-Shiong materially overstated the capabilities of Anktivas, an FDA-approved IL-15 receptor agonist, in public statements, potentially misleading investors about the company's prospects and affecting their investment decisions.
- FDA Warning Letter: On March 24, 2026, the FDA issued a warning letter to ImmunityBio, stating that its TV ad and podcast were deemed “false or misleading,” which could damage the company's reputation and impact its market performance moving forward.
- Stock Price Plunge: Following the FDA's warning, ImmunityBio's stock price fell from $9.40 per share on March 23, 2026, to $7.41, a decline of 21.2%, reflecting a significant loss of market confidence in the company's future, which may hinder its financing and operational capabilities.
See More
Securities Fraud Class Action Filed Against ImmunityBio, Inc.
- Lawsuit Background: Kessler Topaz Meltzer & Check, LLP has filed a securities fraud class action against ImmunityBio, Inc. (NASDAQ:IBRX) on behalf of investors who purchased shares between January 19, 2026, and March 24, 2026, highlighting serious concerns regarding the company's financial transparency.
- False Statement Allegations: The lawsuit alleges that ImmunityBio made materially false and misleading statements during this period, particularly regarding the capabilities of its cancer vaccine Anktiva, which misled investors about the company's prospects and could negatively impact its stock price and market trust.
- FDA Warning Impact: On March 24, 2026, the FDA issued a warning letter to ImmunityBio, citing inaccurate claims made by executives about Anktiva on a podcast, resulting in a 21.12% drop in stock price, raising investor concerns about corporate governance and compliance.
- Investor Action Recommendations: Investors are encouraged to apply for lead plaintiff status by May 26, 2026, to represent all affected investors, indicating a focus on the company's future legal and financial responsibilities.
See More
ImmunityBio Faces Securities Class Action Lawsuit
- Lawsuit Background: ImmunityBio faces a securities class action lawsuit following misleading efficacy claims made by its Chief Scientific Officer regarding its lead biologic product Anktiva, resulting in a stock price drop of over 21% on March 24, 2026, erasing nearly $2 billion in market capitalization.
- FDA Warning Letter: The FDA issued a warning letter to ImmunityBio, stating that its promotional materials, including a podcast and TV ad, contained false or misleading information, particularly regarding claims that Anktiva could cure all cancers, lacking sufficient clinical data to support such assertions.
- Investor Rights: National shareholder rights firm Hagens Berman is investigating whether ImmunityBio violated federal securities laws, urging investors who suffered significant losses to submit claims and encouraging witnesses to provide information to assist in the investigation.
- Market Reaction: The stock price decline following the FDA warning and subsequent lawsuit reflects market concerns about ImmunityBio's future prospects, potentially impacting its ability to raise funds and maintain investor confidence.
See More
ImmunityBio Class Action Reminder for Investors
- FDA Warning Letter: On March 24, 2026, the FDA issued a warning to ImmunityBio, stating that Executive Chairman Patrick Soon-Shiong made false claims on a podcast regarding the company's lead biologic product, Anktiva, asserting it could 'cure and prevent all cancer,' exposing the company to legal risks.
- Stock Price Plunge: Following the FDA warning, ImmunityBio's stock price fell by $1.98, or 21.12%, closing at $7.42 per share, which directly impacted investors' asset values and resulted in significant losses.
- Class Action Context: The class action lawsuit alleges that the company made materially false and misleading statements during the class period, failing to disclose the true capabilities of Anktiva, which may mislead investors about the company's prospects and affect future investment decisions.
- Investor Action Notice: Investors are reminded to file their lead plaintiff motions by May 26, 2026, to seek compensation for their investment losses, highlighting the importance of timely action in the legal process.
See More
ImmunityBio Faces Securities Class Action Lawsuit
- Lawsuit Timeline: Investors must file Lead Plaintiff applications by May 26, 2026, to participate in the securities class action against ImmunityBio, covering stock transactions from January 19 to March 24, 2026, highlighting investor concerns over potential losses.
- FDA Warning Impact: Following a March 13, 2026, warning letter from the FDA indicating misleading advertising for Anktiva, ImmunityBio's stock price plummeted by 21% or $1.98 per share on March 24, 2026, demonstrating the direct impact of regulatory risks on the company's valuation.
- Legal Accountability: The lawsuit alleges that ImmunityBio and its executives failed to disclose material information during the class period, violating federal securities laws, indicating significant deficiencies in the company's transparency that could lead to severe legal repercussions.
- Investor Rights Protection: Kahn Swick & Foti law firm urges affected investors to contact their managing partner to understand their legal rights, emphasizing the importance of seeking compensation in securities fraud cases, reflecting a commitment to protecting investor interests.
See More
